Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Fierce Pharma15h
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...
Eli Lilly and Novo Nordisk are tackling heart health next
After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...
Novo Nordisk Stock (NVO) Drops Despite Positive GLP-1 Trial Data
Novo Nordisk (NVO) stock dropped on Monday despite the drugmaker reporting positive results for its GLP-1 medicine, Rybelsus. A clinical trial ...
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and ...
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
NBC New York3d
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...